Status:
COMPLETED
Study on the Pharmacokinetics (PK) of DFN-15 vs Comparator and Food-effect on DFN-15 PK in Healthy Adult Subjects
Lead Sponsor:
Dr. Reddy's Laboratories Limited
Conditions:
Migraine
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
An Open-Label, Three-Way Randomized, Single Dose Crossover Study Comparing Bioavailability of DFN-15 under fasting conditions versus Comparator under fed conditions and to determine food-effect of DFN...
Eligibility Criteria
Inclusion
- Healthy, adult, male or female 19-55 years of age, inclusive, at screening.
- Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee.
- Females of childbearing potential: must either be sexually inactive (abstinent) for 30 days prior to the first dose and throughout the study or be using birth control method; Female subjects of non-childbearing potential and must have undergone sterilization procedures or be postmenopausal for at least 1 year prior
- Male subject must agree to use contraception or abstain during the study until 90 days beyond the last dose of study drug.
- Understands the study procedures in the informed consent form (ICF), and willing and able to comply with the protocol.
Exclusion
- History or presence of hypersensitivity or idiosyncratic reaction to celecoxib, sulfonamides, aspirin or other NSAIDs or related compounds
- History or presence of clinically significant medical or psychiatric condition or disease
- History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study
- liver enzyme tests greater than the upper limit of normal at screening
- Estimated creatinine clearance \<90 mL/minute at screening
- History or presence of alcoholism
- History or presence of bilateral pedal edema or generalized edema or fluid retention
- Female subjects who are pregnant or lactating or actively trying to conceive
- Positive urine drug or alcohol results at screening or check-in
- Positive cotinine at screening
- Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV)
- Seated blood pressure is less than 90/60 mmHg or greater than 140/90 mmHg at screening
- Seated heart rate is lower than 45 bpm or higher than 100 bpm at screening
- Has been on a diet incompatible with the on-study diet
- Unable to refrain from or anticipates the use of prohibited medications
- Donation of blood or significant blood loss within 56 days prior to the first dose of study drug; plasma donation within 7 days prior to the first dose of study drug
- Participation in another clinical trial within 28 days prior to the first dose of study drug
Key Trial Info
Start Date :
June 9 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 12 2018
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT03282838
Start Date
June 9 2017
End Date
January 12 2018
Last Update
February 13 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Celerion
Lincoln, Nebraska, United States, 68502